Hypertensive emergency is defined as SBP/DBP >180/110–120 mm Hg with evidence of new or worsening target-organ damage to the brain, arteries, retina, kidney, or heart (BARKH mnemonic). [1] It is distinct from asymptomatic markedly elevated BP (formerly "hypertensive urgency"), which lacks end-organ damage and does not require aggressive parenteral therapy. [2-3] Nonadherence to previously prescribed antihypertensive medications is the most common precipitant. [3] In-hospital mortality ranges from 0.2% to 11%, and the most common forms of target-organ damage are ischemic stroke (28%), acute HF/pulmonary edema (24%), and hemorrhagic stroke (15%). [3-4]
The following ACC/AHA guideline algorithm outlines the diagnostic and management framework:
1. History
- Duration and severity of pre-existing hypertension; baseline BP readings if available
- Current antihypertensive medications, doses, and adherence — nonadherence is the #1 precipitant [3]
- Symptom characterization: headache, chest pain, back pain (aortic dissection), dyspnea, visual changes, focal neurologic deficits, seizures, altered consciousness [3][6]
- Timing: acute onset vs. gradual; recent medication changes, missed doses
- Triggers: illicit drug use (cocaine, amphetamines), sympathomimetics, OTC decongestants, MAOIs, dietary tyramine, clonidine withdrawal [2][6]
- Pregnancy status in women of childbearing age
- Important negatives: absence of chest pain, dyspnea, neurologic symptoms, visual changes, hematuria
2. Alarm Features
- Chest pain → ACS, aortic dissection, acute HF [6]
- Tearing back/interscapular pain with BP differential between arms → aortic dissection [6]
- Acute dyspnea, orthopnea, pink frothy sputum → flash pulmonary edema [2]
- Focal neurologic deficit, aphasia, hemiparesis → stroke (ischemic or hemorrhagic) [3]
- Seizures, altered mental status, visual loss → hypertensive encephalopathy / PRES [3][7]
- Oliguria, hematuria → acute kidney injury [7]
- Headache with meningismus → subarachnoid hemorrhage
- Microangiopathic hemolytic anemia + thrombocytopenia → thrombotic microangiopathy / malignant hypertension [3][7]
3. Medications
Contributory medications:
- Sympathomimetics (pseudoephedrine, phenylephrine), NSAIDs, oral contraceptives, corticosteroids, erythropoietin, calcineurin inhibitors, VEGF inhibitors
- Illicit: cocaine, methamphetamine
- MAOIs + tyramine interaction
- Clonidine or beta-blocker withdrawal (rebound hypertension) [2]
Contraindicated medications in specific scenarios:
- Beta-blockers contraindicated in acute pulmonary edema, cocaine toxicity, and decompensated HF [2-3]
- Hydralazine generally avoided as first-line due to unpredictable response and prolonged duration [2-3]
- ACE inhibitors/ARBs/nitroprusside contraindicated in eclampsia/preeclampsia [2]
- Nitroglycerin contraindicated with recent PDE-5 inhibitor use and in volume-depleted patients [2]
4. Diet
- Sodium restriction is a cornerstone of long-term management; excessive sodium intake contributes to resistant hypertension
- Tyramine-rich foods (aged cheese, cured meats, fermented products) are dangerous in patients on MAOIs
- Licorice (glycyrrhizin) can cause mineralocorticoid excess hypertension
- Adequate hydration — many patients with malignant hypertension are volume-depleted from pressure natriuresis [7]
- Long-term: DASH diet (Dietary Approaches to Stop Hypertension), potassium-rich foods, alcohol moderation
5. Review of Systems
- Neuro: headache, visual changes, confusion, seizures, focal weakness, speech difficulty
- Cardiac: chest pain, palpitations, dyspnea on exertion, orthopnea, PND, lower extremity edema
- Vascular: tearing chest/back pain, claudication, pulse asymmetry
- Renal: decreased urine output, hematuria, foamy urine
- Ophthalmologic: blurred vision, scotomata, vision loss
- GI: nausea, vomiting (encephalopathy or posterior fossa pathology)
6. Collateral History and Family History
- Confirm medication list and adherence from pharmacy records, family, or caregivers
- Prior ED visits or hospitalizations for hypertensive crises
- Family history of early-onset hypertension, pheochromocytoma, renal disease, stroke, aortic dissection, or polycystic kidney disease
- Social context: substance use (cocaine, methamphetamine), access to medications, insurance barriers to adherence [3]
7. Risk Factors
- Age >60, Black race, uninsured/underinsured, lower socioeconomic status [3]
- Chronic uncontrolled hypertension with medication nonadherence [3]
- CKD, renovascular disease, primary aldosteronism, pheochromocytoma
- Illicit drug use (cocaine, amphetamines)
- Pregnancy (preeclampsia/eclampsia)
- Obstructive sleep apnea, obesity
- Comorbid diabetes, hyperlipidemia, smoking
8. Differential Diagnosis
The key clinical decision is distinguishing true hypertensive emergency (with end-organ damage) from asymptomatic markedly elevated BP (without end-organ damage). [1] Target-organ damage can manifest even below the 180/120 threshold in certain contexts (e.g., eclampsia, pheochromocytoma). [1][3]
Cannot-miss diagnoses presenting with severe hypertension:
- Aortic dissection — least common but highest acuity; BP differential between arms, tearing pain [2][4]
- Acute ischemic or hemorrhagic stroke — most common end-organ damage overall [4]
- Pheochromocytoma crisis — paroxysmal hypertension, diaphoresis, headache, palpitations [2]
- Eclampsia/preeclampsia — in pregnant or postpartum patients [2]
- Thrombotic microangiopathy (TTP/HUS vs. malignant hypertension) — schistocytes, thrombocytopenia, AKI [7]
Mimics of hypertensive emergency:
- Pain- or anxiety-driven BP elevation (resolves with treatment of underlying cause)
- Acute urinary retention, medication effect, white-coat response in acute care setting [1]
9. Past Medical History
- Prior hypertensive emergencies or urgencies
- Known CKD, prior AKI, dialysis history
- History of stroke, MI, HF, aortic aneurysm
- Known secondary causes: renal artery stenosis, pheochromocytoma, Cushing syndrome, coarctation
- Surgical history: prior aortic or renal surgery
- Chronic illnesses affecting management: COPD/asthma (limits beta-blocker use), liver disease (limits nitroprusside), advanced aortic stenosis (limits nicardipine)
10. Physical Exam
- Vitals: BP in both arms (>20 mmHg difference suggests aortic dissection); HR (tachycardia suggests catecholamine excess or HF; bradycardia limits beta-blocker use); RR, SpO2 [6]
- Fundoscopy: flame hemorrhages, cotton-wool spots, papilledema — distinguishes true emergency from urgency [6][8]
- Cardiovascular: JVD, S3/S4 gallop, new murmur, crackles (pulmonary edema), bilateral pulse comparison [1][6]
- Neurologic: level of consciousness, cranial nerves, motor/sensory exam, pronator drift, gait, speech [6]
- Abdominal: renal artery bruits (renovascular disease), pulsatile mass (AAA)
- Extremities: peripheral edema, pulse deficits
11. Lab Studies
Recommended initial labs: [1][3][7-8]
- BMP (creatinine, BUN, electrolytes — assess AKI, hypokalemia from hyperaldosteronism)
- CBC with peripheral smear (schistocytes → TMA/malignant hypertension)
- Troponin (rule out myocardial injury)
- BNP/NT-proBNP (if HF suspected)
- Urinalysis (proteinuria, hematuria, RBC casts)
- LDH, haptoglobin (hemolysis workup if TMA suspected) [7]
- Urine drug screen (cocaine, amphetamines) [7]
Expected abnormalities:
- Elevated creatinine in 60–70% of malignant hypertension cases [7]
- Hypokalemia in ~50% of malignant hypertension (RAAS activation) [7]
- Hyponatremia from angiotensin II–mediated ADH stimulation [7]
12. Imaging
- Chest X-ray: first-line — assess for pulmonary edema, widened mediastinum (aortic dissection), cardiomegaly [1][8]
- CT head without contrast: if neurologic symptoms — rule out ICH, ischemic stroke, PRES [7]
- CT angiography of chest/abdomen/pelvis: if aortic dissection suspected (gold standard)
- Brain MRI: preferred for PRES, posterior fossa lesions, and subtle ischemic changes [7]
- Renal ultrasound with Doppler: if renovascular disease suspected (not acute)
- TTE: assess LV function, wall motion abnormalities, LVH [7]
Imaging is unnecessary in asymptomatic markedly elevated BP without end-organ damage. [3]
13. Special Tests
- BARKH assessment (Brain, Arteries, Retina, Kidney, Heart) — rapid bedside framework for target-organ screening [1]
- Fundoscopic exam — critical point-of-care test; high-grade retinopathy (grade III/IV) confirms hypertensive emergency [6-7]
- Bedside echocardiography (POCUS) — assess LV function, pericardial effusion, wall motion
- Urine albumin-to-creatinine ratio — quantify renal damage [7]
- Secondary hypertension workup (after acute stabilization): plasma metanephrines, renin/aldosterone ratio, renal artery imaging, cortisol [7]
14. ECG
Indications: all patients with markedly elevated BP [1][8]
Key findings:
- LVH (Sokolow-Lyon or Cornell criteria) — chronic hypertensive heart disease
- ST-segment depression/elevation → ACS
- T-wave inversions (diffuse) → strain pattern or myocardial ischemia
- Atrial fibrillation/flutter — may be precipitated by or coexist with hypertensive emergency
- Peaked T-waves, QRS widening → hyperkalemia (in setting of AKI)
- Low voltage, electrical alternans → pericardial effusion (rare)
15. Assessment
Severity stratification is based on the type and extent of target-organ damage, not the absolute BP number alone. [1][3] Both the absolute BP level and the pace of rise determine risk — a previously normotensive patient can develop end-organ damage at lower thresholds (e.g., 160/100 in eclampsia). [3]
Common presentations by organ system: [4]
Complications to anticipate:
- Overshoot hypotension (occurs in ~10% of patients; associated with increased mortality) [3]
- Cerebral hypoperfusion from overly aggressive BP lowering in chronically hypertensive patients (rightward-shifted autoregulation curve) [3]
- Rebound hypertension after IV drug discontinuation [3]
16. Treatment Plan
Initial stabilization: IV access, continuous cardiac monitoring, arterial line for continuous BP monitoring (especially with nitroprusside). [2-3]
BP targets by condition (per 2025 AHA/ACC guidelines and NEJM review): [2-3]
Key pharmacologic pearls:
- Nicardipine achieves target BP faster than labetalol with less BP variability [2-3]
- Clevidipine achieves faster BP reduction than nicardipine with less variability [2-3]
- Hydralazine should generally be avoided as first-line (unpredictable, prolonged effect) [2-3]
- Start or restart oral antihypertensives 6–12 hours after initiating IV therapy to facilitate transition and prevent rebound [3]
- If overshoot hypotension occurs: stop IV drip immediately, consider vasopressors and/or IV fluids [3]
17. Disposition
- ICU admission: all true hypertensive emergencies requiring IV antihypertensive infusions [3]
- Observation/step-down: patients with rapidly controlled BP and resolving symptoms, or those with borderline end-organ findings
- Discharge from ED: asymptomatic markedly elevated BP without end-organ damage — reinstitute or intensify oral antihypertensives, arrange close outpatient follow-up within 24–72 hours [1-2]
- Specialist consultation triggers: neurosurgery (ICH, SAH), cardiothoracic surgery (aortic dissection), nephrology (AKI/TMA), OB (eclampsia), ophthalmology (severe retinopathy)
18. Follow-Up / Return Precautions
- Patients discharged with asymptomatic elevated BP: follow-up within 24–72 hours with PCP or hypertension specialist
- Medication reconciliation and adherence counseling at discharge — address barriers (cost, side effects, health literacy)
- Return precautions: severe headache, chest pain, shortness of breath, visual changes, weakness/numbness, slurred speech, decreased urine output, confusion
- Expected recovery: BP should normalize over 24–48 hours with appropriate IV therapy; oral regimen optimization over weeks
- Screen for secondary hypertension after stabilization if clinically indicated (young age, resistant hypertension, hypokalemia, renal bruits) [7]
- Long-term: target BP <130/80 mmHg for most adults per 2025 AHA/ACC guidelines [2]
References
1. The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association. — Bress AP, Anderson TS, Flack JM, et al. Hypertension. 2024.
2. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Jones DW, Ferdinand KC, Taler SJ, et al. Journal of the American College of Cardiology. 2025.
3. Acute Severe Hypertension. — Peixoto AJ. The New England Journal of Medicine. 2019.
4. Clinical Outcomes in Hypertensive Emergency: A Systematic Review and Meta-Analysis. — Siddiqi TJ, Usman MS, Rashid AM, et al. Journal of the American Heart Association. 2023.
5. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management Of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. — Whelton PK, Carey RM, Aronow WS, et al. Journal of the American College of Cardiology. 2018.
6. Hypertensive Emergencies. — Vaughan CJ, Delanty N. Lancet. 2000.
7. Malignant Hypertension:A Systemic Cardiovascular Disease: JACC Review Topic of the Week. — Boulestreau R, Śpiewak M, Januszewicz A, et al. Journal of the American College of Cardiology. 2024.
8. Treatment of Hypertensive Crisis. — Calhoun DA, Oparil S. The New England Journal of Medicine. 1990.